Results: Those treated with orlistat showed greater weight loss (–9.4±2.3 vs.–4.9±1.3 kg, p<
0.05) and decrease of fat mass (–5.4±3.0 vs.–3.5±0.7 kg, p< 0.05) than those treated with …

BACKGROUND AND AIM: Orlistat and metformin are the currently used drugs for weight
loss. We aimed to compare the effect of orlistat and orlistat plus metformin combination …

Aim: Obesity is associated with an altered GH/IGF-I axis status, accounting for the increased
cardiovascular risk in obese subjects with GH deficiency. Aim of this randomized, simple …

Objective: Sibutramine and orlistat are currently used for weight loss. We aimed to
investigate the effect of orlistat and sibutramine combination therapy in treatment of obese …

Aims The aim of this study was to assess the effects of orlistat on weight loss‐related clinical
variables in overweight/obese women with polycystic ovary syndrome (PCOS) and to …

Diabetes increases the risk of cardiovascular disease (CVD) more in women (W) than men
(M), perhaps because diabetes has more deleterious effects on risk factors in women or …

Aims To assess the effects of orlistat vs. placebo, in combination with a weight management
programme, on weight loss and metabolic control in obese patients with Type 2 diabetes …

Orlistat lowers lipids and improves insulin sensitivity, but its effect on other metabolic
syndrome related parameters is not known. To assess its influence on adiponectin, high …

Objective: Both orlistat and sibutramine are anti-obesity drugs with a well-documented
efficacy in weight reduction. The aim of presen study was to assess comparatively the …

OBJECTIVE Obesity is an important risk factor for type 2 diabetes. Weight loss in patients
with type 2 diabetes is associated with improved glycemic control and reduced …